Verastem to Present at the Stifel Nicolaus 2011 Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it will be presenting at the Stifel Nicolaus 2011 Healthcare Conference at 2:40 pm EST on Wednesday, September 7, 2011. The presentation will focus on the Company's strategy for translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers.

About Verastem, Inc.

Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal. Verastem is backed by Advanced Technology Ventures, Astellas Venture Management, Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund and MPM Capital. For more information, please visit www.verastem.com.



CONTACT:

For Verastem, Inc.
Lacy Roosevelt, 617-520-7052
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.